BriaCell Therapeutics Corp.
BCTX · NASDAQ
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $30 | $37 | $21 | $10 |
| G&A Expenses | $6 | $0 | $0 | $0 |
| SG&A Expenses | $6 | $8 | $11 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $0 | $0 | $0 |
| Operating Expenses | $38 | $45 | $31 | $19 |
| Operating Income | -$38 | -$46 | -$31 | -$19 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $39 | $4 | -$15 |
| Pre-Tax Income | -$37 | -$7 | -$27 | -$34 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36 | -$7 | -$27 | -$34 |
| % Margin | – | – | – | – |
| EPS | -86.25 | -59.69 | -261.86 | -330.38 |
| % Growth | -44.5% | 77.2% | 20.7% | – |
| EPS Diluted | -86.25 | -59.69 | -261.86 | -330.38 |
| Weighted Avg Shares Out | 0 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 0 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$37 | -$7 | -$27 | -$34 |
| % Margin | – | – | – | – |